Loading stock data…
AQST
$4.20+0.10 (+2.44%)
Market ClosedLast close May 1
Aquestive Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aquestive Therapeutics, Inc. in the Healthcare sector is trading at $4.20. The stock is currently 44% below its 52-week high of $7.55, remaining 13.6% below its 200-day moving average. Technical signals show neutral RSI of 51 and bearish MACD signal, explaining why AQST maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.20
Potential Upside
5%
Whystock Fair Value$4.41
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of b...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$506.49M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.53
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
193.22%
Volume
Today's trading volume
961,555
Recent News
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Aquestive Therapeutics (AQST) Awaits Anaphylm NDA Approval in Q3
Aquestive Therapeutics Inc. (NASDAQ:AQST) is one of the 7 best small-cap drug manufacturing stocks to buy according to hedge funds. On March 5, Alliance Global reduced the firm’s price target on Aquestive Therapeutics Inc. (NASDAQ:AQST) from $12 to $9. The firm maintained its Buy rating on the shares. The move follows the company’s fourth quarter […]
Aquestive Therapeutics Targets Q3 Anaphylm Resubmission After FDA CRL Flags Human Factors, PK Data
Aquestive Therapeutics (NASDAQ:AQST) executives used the Citizens Life Sciences Conference to outline the company’s path forward after receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration for Anaphylm, its oral film epinephrine product candidate for serious allergic
Aquestive Therapeutics Targets Q3 Anaphylm FDA Resubmission After CRL, Details Launch Plans at Leerink Conf
Aquestive Therapeutics (NASDAQ:AQST) executives used a presentation at the Leerink Global Healthcare Conference to outline the company’s strategic priorities, provide an update on its lead program Anaphylm following a recent FDA complete response letter (CRL), and discuss commercial planning, financ
Aquestive Therapeutics Q4 Earnings Call Highlights
Aquestive Therapeutics (NASDAQ:AQST) executives used the company’s fourth-quarter 2025 earnings call to outline a path forward for Anaphylm, its orally delivered epinephrine product candidate, following a Complete Response Letter (CRL) from the U.S. Food and Drug Administration. Management reiterate